标题
Antibody–Drug Conjugates: The Last Decade
作者
关键词
-
出版物
Pharmaceuticals
Volume 13, Issue 9, Pages 245
出版商
MDPI AG
发表日期
2020-09-14
DOI
10.3390/ph13090245
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Les immuno-conjugués en oncologie
- (2020) Alain Beck et al. M S-MEDECINE SCIENCES
- Les immunoconjugués en oncologie
- (2020) Alain Beck et al. M S-MEDECINE SCIENCES
- Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future
- (2019) Alain Beck et al. Expert Review of Proteomics
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
- (2019) Takashi Nakada et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- THE ANTI-CD25 ANTIBODY-DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT-301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES
- (2019) F. Spriano et al. HEMATOLOGICAL ONCOLOGY
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- (2019) Brad S. Kahl et al. CLINICAL CANCER RESEARCH
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells
- (2018) Philip E. Brandish et al. BIOCONJUGATE CHEMISTRY
- Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
- (2018) Glenwood D. Goss et al. CANCER
- Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
- (2018) Yiwen You et al. DRUG DELIVERY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France
- (2018) Camille Martin et al. mAbs
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody–drug conjugates
- (2018) Francesca Bryden et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway
- (2018) Sauveur Juliette et al. Oncotarget
- Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro
- (2018) Nicolas Aubrey et al. BIOCONJUGATE CHEMISTRY
- Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study
- (2018) Anton Hagenbeek et al. HAEMATOLOGICA
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy
- (2017) Nicolas Joubert et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins
- (2017) Jared L. Spidel et al. mAbs
- A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise
- (2017) Hui Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments
- (2017) Aiko Nagayama et al. Targeted Oncology
- From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
- (2016) Julia Mantaj et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
- (2016) Takashi Nakada et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
- (2016) F. Li et al. CANCER RESEARCH
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
- (2016) Bishoy Faltas et al. Clinical Genitourinary Cancer
- New developments for antibody-drug conjugate-based therapeutic approaches
- (2016) Bart ECG de Goeij et al. CURRENT OPINION IN IMMUNOLOGY
- Antibody-drug conjugates for non-oncological indications
- (2016) Renhe Liu et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Prospects and progress of antibody-drug conjugates in solid tumor therapies
- (2016) Serengulam V. Govindan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates
- (2016) Alain Beck et al. Expert Review of Proteomics
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
- (2016) M. Dorywalska et al. MOLECULAR CANCER THERAPEUTICS
- Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
- (2016) C.-H. Chang et al. MOLECULAR CANCER THERAPEUTICS
- ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
- (2016) A. C. Phillips et al. MOLECULAR CANCER THERAPEUTICS
- Increment in Drug Loading on an Antibody–Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro
- (2016) Guillaume Brachet et al. MOLECULAR PHARMACEUTICS
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Processes for Constructing Homogeneous Antibody Drug Conjugates
- (2016) David Y. Jackson ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
- (2016) Jose F. Ponte et al. NEOPLASIA
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing
- (2015) Wayne C. Widdison et al. BIOCONJUGATE CHEMISTRY
- Targeted Delivery of LXR Agonist Using a Site-Specific Antibody–Drug Conjugate
- (2015) Reyna K. V. Lim et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
- (2015) K. J. Hamblett et al. CANCER RESEARCH
- Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody–drug conjugate (ADC)
- (2015) João P. M. Nunes et al. CHEMICAL COMMUNICATIONS
- A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
- (2015) S.-F. Yu et al. CLINICAL CANCER RESEARCH
- Emerging formats for next-generation antibody drug conjugates
- (2015) Mahendra P Deonarain et al. Expert Opinion on Drug Discovery
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
- (2015) Giulio Casi et al. JOURNAL OF MEDICINAL CHEMISTRY
- An Immunosuppressive Antibody–Drug Conjugate
- (2015) Rongsheng E. Wang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
- (2015) M Pfeifer et al. LEUKEMIA
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates
- (2015) R. Gebleux et al. MOLECULAR CANCER THERAPEUTICS
- CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
- (2015) R. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
- (2015) Christopher R. Behrens et al. MOLECULAR PHARMACEUTICS
- Noninternalizing Targeted Cytotoxics for Cancer Therapy
- (2015) Giulio Casi et al. MOLECULAR PHARMACEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Homed to the hideout
- (2015) Wolf-Dietrich Hardt NATURE
- Novel antibody–antibiotic conjugate eliminates intracellular S. aureus
- (2015) Sophie M. Lehar et al. NATURE
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- An Anti-CD79B Antibody-Drug Conjugate Is Active in Non-Hodgkin Lymphoma
- (2015) Cancer Discovery
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
- (2014) George Badescu et al. BIOCONJUGATE CHEMISTRY
- Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging
- (2014) Sam Massa et al. BIOCONJUGATE CHEMISTRY
- Versatility of Microbial Transglutaminase
- (2014) Pavel Strop BIOCONJUGATE CHEMISTRY
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
- (2014) E. Perrino et al. CANCER RESEARCH
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema
- (2014) J. A. Carlson et al. NEURO-ONCOLOGY
- Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging
- (2014) Felix F. Schumacher et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Risks and untoward toxicities of antibody-based immunoconjugates
- (2012) Dana Litvak-Greenfeld et al. ADVANCED DRUG DELIVERY REVIEWS
- Highly efficient disulfide bridging polymers for bioconjugates from radical-compatible dithiophenol maleimides
- (2012) Mathew W. Jones et al. CHEMICAL COMMUNICATIONS
- Antibody–drug conjugates: Basic concepts, examples and future perspectives
- (2012) Giulio Casi et al. JOURNAL OF CONTROLLED RELEASE
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
- (2012) H. K. Erickson et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the Hemoglobin Scavenger receptor CD163 in Macrophages Highly Increases the Anti-inflammatory Potency of Dexamethasone
- (2012) Jonas H Graversen et al. MOLECULAR THERAPY
- Cancer stromal targeting (CAST) therapy
- (2011) Yasuhiro Matsumura ADVANCED DRUG DELIVERY REVIEWS
- Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor Tissue
- (2011) Masahiro Yasunaga et al. BIOCONJUGATE CHEMISTRY
- New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots
- (2011) Masahiro Yasunaga et al. CANCER SCIENCE
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Les immunoconjugués, anticorps « armés » pour combattre le cancer
- (2011) Jean-François Haeuw et al. M S-MEDECINE SCIENCES
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
- (2009) Hans K. Erickson et al. BIOCONJUGATE CHEMISTRY
- Antibody-Drug Conjugate Targets
- (2009) B. Teicher CURRENT CANCER DRUG TARGETS
- Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
- (2008) Stephen C. Alley et al. BIOCONJUGATE CHEMISTRY
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started